Medtronic stock: FDA clears AI algorithms for LINQ II
Published on 11/16/2026 at 17:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory move expands cardiac monitoring
- The FDA approved two artificial intelligence algorithms for Medtronic's LINQ II cardiac monitor on November 12.
- The applications are designed to support diagnosis for people with heart rhythm abnormalities.
Medtronic received a fresh regulatory boost on Thursday, November 12, when the U.S. Food and Drug Administration approved two artificial intelligence algorithms for use with its LINQ II cardiac monitor. Pharmaphorum reported that the applications are designed to help diagnose people with heart rhythm abnormalities.
AI tools add to cardiac portfolio
The approval links software-based analysis with Medtronic's implantable monitoring platform. The decision gives physicians additional tools for reviewing heart rhythm data and broadens the technology layer around the LINQ II system.
The regulatory action is a product and market-access development rather than a reported financial forecast. The report does not attach a sales estimate or earnings contribution to the algorithms, leaving adoption and commercial impact as the next investor questions.
Investors await operational evidence
For investors, the approval adds another cardiology development ahead of Medtronic's next operating update. The commercial relevance will depend on physician uptake, use of the monitoring platform and whether the new functions support demand across the company's cardiac portfolio.
Medtronic stock traded at 93.74 euros on Lang & Schwarz at 5:31 p.m. CET on Monday, November 16, 2026.
Medtronic plc at a glance
- Company: Medtronic plc
- ISIN: IE00BTN1Y115
- Ticker: MDT
- Quoted at: Lang & Schwarz
- Price: 93.74 euros at 5:31 p.m. CET on Monday, November 16, 2026
Healthcare investors can follow Current market reports for broader market developments.
See More news and analyses on Medtronic stock.
Pharmaphorum reported the FDA approval and described the intended use of the two algorithms with the LINQ II cardiac monitor.
